Saxagliptin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Saxagliptin · Onglyza
Rights held by AstraZeneca and partners; US product discontinued
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: February 2027 · NCT02969798 (registry estimate)
Reported efficacy
Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)
Result source: NCT00121667
Sitagliptin · Januvia
Marketed by Merck & Co. and partners
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)
Result source: NCT00086502
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Saxagliptin | Sitagliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.3%−0.4 vs placeboNCT0075758819 other results
| -0.6% vs 0.2%−0.8 vs placeboNCT000875167 other results
|
| Body weight, change (kg) | -1.9 vs -0.4−1.5 vs placeboNCT016463207 other results
| -0.5 vs -1.4vs Oral SemaglutideNCT040178321 other result
|
| HbA1c below 7% | 44.4% vs 16.6%+27.8 vs placeboNCT0012166715 other results
| 49.5% vs 36.8%+12.7 vs placeboNCT014856144 other results
|
| Fasting plasma glucose, change | -0.6 vs -0.3−0.2 vs placeboNCT0075758811 other results
| -0.7 vs 0.3−0.9 vs placeboNCT000875167 other results
|
| 3-point MACE (% with event) | 7.4% vs 7.4%±0 vs placeboNCT01107886 | —Not posted · NCT01529541 |
HbA1c, change
- Saxagliptin
- -0.7% vs -0.3%−0.4 vs placeboNCT00757588
19 other results
- 7.1% vs 7.5% NCT00661362
- -0.5% vs -0.2% NCT01619059
- 0.1% vs 0.5% NCT03199053
- -0.8% vs -0.1% NCT01646320
- -0.7% vs -0.1% NCT01128153
- -0.7% vs 0.6% NCT01204775
- -1% vs 0.9% NCT01434186
- -1.4% vs -1.0% NCT02419612
- -1.4% vs -1.1% NCT02284893
- -1.7% vs -1.5% NCT02551874
- -1.0% vs -0.7% NCT02681094
- -0.2% vs -0.7% NCT03199053
- 0.1% vs -0.7% NCT03199053
- -0.8% vs -1.0% NCT02471404
- -1.2% vs -1.0% NCT02471404
- -0.8% vs -0.8% NCT02243176
- -0.8% vs -0.8% NCT02243176
- -0.5% vs -0.4% NCT01006590
- -0.4% vs -0.6% NCT01006603
- Sitagliptin
- -0.6% vs 0.2%−0.8 vs placeboNCT00087516
7 other results
- -0.8% vs -0.1% NCT00086502
- -0.8% vs 0.2% NCT00087516
- -0.0% vs 0.2% NCT01485614
- -1.1% vs -0.7% NCT02791490
- -0.1% vs -1.0% NCT01485614
- -0.2% vs -0.7% NCT01485614
- -0.5% vs -1.1% NCT01907854
Body weight, change (kg)
- Saxagliptin
- -1.9 vs -0.4−1.5 vs placeboNCT01646320
7 other results
- -3.1 vs 0.9 NCT02419612
- -1.9 vs -0.5 NCT02284893
- -1.5 vs 2.1 NCT02551874
- -2.0 vs -0.4 NCT02681094
- -3.5 vs 1.8 NCT02471404
- -3.1 vs 1.8 NCT02471404
- -1.4 vs -2.0 NCT02243176
- Sitagliptin
- -0.5 vs -1.4vs Oral SemaglutideNCT04017832
1 other result
- -1.8 vs -3.3 NCT01907854
HbA1c below 7%
- Saxagliptin
- 44.4% vs 16.6%+27.8 vs placeboNCT00121667
15 other results
- 41.1% vs 23.9% NCT00121641
- 43.5% vs 16.6% NCT00121667
- 37.9% vs 23.9% NCT00121641
- 22.1% vs 13.3% NCT00918879
- 45.8% vs 28.8% NCT00698932
- 37.1% vs 16.6% NCT00121667
- 35% vs 23.9% NCT00121641
- 37.5% vs 24.2% NCT00885378
- 21.3% vs 10% NCT03199053
- 36.7% vs 13.3% NCT01646320
- 21.4% vs 11.7% NCT02419612
- 44.3% vs 34.3% NCT02419612
- 37.3% vs 25.1% NCT02284893
- 37.2% vs 26.1% NCT00960076
- 38.3% vs 41.5% NCT02243176
- Sitagliptin
- 49.5% vs 36.8%+12.7 vs placeboNCT01485614
4 other results
- 28.8% vs 16.6% NCT02791490
- 15.6% vs 5.7% NCT02791490
- 28.4% vs 33.3% NCT01485614
- 49.5% vs 77.8% NCT01485614
Fasting plasma glucose, change
- Saxagliptin
- -0.6 vs -0.3−0.2 vs placeboNCT00757588
11 other results
- -0.5 vs -0.3 NCT01619059
- 0.1 vs 0.2 NCT03199053
- -1.8 vs -0.3 NCT01646320
- -0.3 vs 0.1 NCT01128153
- -1.8 vs -0.6 NCT02284893
- -2.4 vs -1.0 NCT03199053
- -0.6 vs -1.0 NCT03199053
- -1.6 vs -1.5 NCT02471404
- -0.7 vs -1.3 NCT01006603
- -2.1 vs -1.5 NCT02471404
- -1.0 vs -1.0 NCT02243176
- Sitagliptin
- -0.7 vs 0.3−0.9 vs placeboNCT00087516
7 other results
- -0.9 vs 0.1 NCT00086502
- -0.9 vs 0.3 NCT00087516
- 0.4 vs 0.3 NCT01485614
- -1.6 vs -0.9 NCT02791490
- -0.5 vs -1.0 NCT04017832
- 0.6 vs -1.1 NCT01485614
- -0.2 vs -1.7 NCT01485614
3-point MACE (% with event)
- Saxagliptin
- 7.4% vs 7.4%±0 vs placeboNCT01107886
- Sitagliptin
- —Not posted · NCT01529541
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. Saxagliptin: 12 of 12 rows · Sitagliptin: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Saxagliptin Rows use multiple source trials | Sitagliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.55 mmol/L @ 24wka,b NCT01608724 · Phase 4 · registry result, not featured evidence 1 other source trial-0.62 mmol/L @ 24wk* NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted | -1.9 mmol/L @ 24wkc,a,b NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-2.03 mmol/L @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.96 mmol/L @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| Glycemic Rescue responder rate · % of participants | 37% (n=227) vs 55.6% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mga,b,d NCT02419612 · Phase 3 · registry result, not featured evidence | 35.8% (n=95) vs 11.1% (n=9) Metformin @ 54wka,b,d NCT01485614 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.64% (n=229) @ 24wke,a NCT02104804 · Phase 3 · registry result, not featured evidence · combination | -1.27% (n=183) @ 24wkc,e,a NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-1.51% (n=189) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.15% (n=187) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c Less Than 7 absolute value · percentage points | 44.7% (n=356) vs 54.7% (n=353) Glimepiride @ 52wk5 mgf,a,b,g NCT01006603 · Phase 4 · registry result, not featured evidence | 26.9% (n=182) vs 50.6% (n=176) Liraglutide @ 26wkf,a,b,g Yes NCT01907854 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than 7 absolute value · percentage points No placebo or comparator arm | 11.4% (n=229) @ 24wke,a NCT02104804 · Phase 3 · registry result, not featured evidence · combination | 49.7% (n=183) @ 24wkc,e,a NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses59.8% (n=189) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination 46.5% (n=187) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c Less Than 7% event count · % of participants | 42.8% (n=290) vs 21.8% (n=289) Dapagliflozin + Metformin @ 24wk*f,a,b,h NCT02681094 · Phase 3 · registry result, not featured evidence · add on · converted to % from 124 Participants as posted | 36.5% (n=334) vs 43.3% (n=321) Oral Semaglutide @ 26wk*100 mgf,a,b,h Yes NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 8.7% (n=23) @ 26wk5 mgc,e,a,i NCT03199053 · Phase 3 · registry result, not featured evidence show 1 more dose15% (n=20) @ 26wk2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence | 26.6% (n=94) @ 20wkc,e,a,i NCT00870194 · Phase 4 · registry result, not featured evidence show 1 more dose41.7% (n=108) @ 20wk NCT00870194 · Phase 4 · registry result, not featured evidence · combination |
| PPG 2h Change mg/dL absolute change · mmol/L | -4.08 vs -2.11 placebo mmol/L @ 24wk*e,a,b,j NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted 2 other source trials-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted -1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted | -6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*e,a,b,j NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted |
| Dropout rate | 22.7%10 mgk NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results25.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 22.9%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 29.6%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 35.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 28.4%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 0% NCT02024477 · Phase 4 · registry result, not featured evidence 10.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 4.5%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT02243176 · Phase 4 · registry result, not featured evidence 17.1% NCT01608724 · Phase 4 · registry result, not featured evidence 2.4% NCT01107886 · Phase 4 · registry result, not featured evidence 19.7%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 19% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 5.7%Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 7.5%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 8.6% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 8.2% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 25% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 6.8%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.5%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.2%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 12.4% NCT01128153 · Phase 3 · registry result, not featured evidence 5.8% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 61.4% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5.6%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 4.3%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 11.8%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 50.6% NCT00614939 · Phase 3 · registry result, not featured evidence 10.8%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 15%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 7.7%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 10.2%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 74.6%100 mgl NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results67.6%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 69.1%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 67.6%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 9% NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0.7%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 10.8%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.7%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.2%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 12.9%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 3% NCT01131182 · Phase 4 · registry result, not featured evidence 20.5%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 10.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence 2.5%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1% NCT01485614 · Phase 3 · registry result, not featured evidence 4.8%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 10.6%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.6% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 2.8%10 mgk NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results3.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.1%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02024477 · Phase 4 · registry result, not featured evidence 2.2%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 0.3%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT02243176 · Phase 4 · registry result, not featured evidence 2% NCT01608724 · Phase 4 · registry result, not featured evidence — NCT01107886 · Phase 4 · registry result, not featured evidence 4.2%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 1.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 0.4%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence — NCT02551874 · Phase 3 · registry result, not featured evidence · combination 3.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 0.4% NCT02284893 · Phase 3 · registry result, not featured evidence · combination — NCT01204775 · Phase 3 · registry result, not featured evidence — NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 1.7%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 1.9%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01128153 · Phase 3 · registry result, not featured evidence 0.7% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 2.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00918879 · Phase 3 · registry result, not featured evidence —5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 5.9% NCT00614939 · Phase 3 · registry result, not featured evidence —2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 0%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 1.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 2.3%100 mgl NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results4.2%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence — NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT02318693 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 1.5%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1.5%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence —Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination — NCT01131182 · Phase 4 · registry result, not featured evidence 7.9%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 3.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination — NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence —100 mg NCT04017832 · Phase 3 · registry result, not featured evidence — NCT01485614 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 0.5% NCT03115112 · Phase 3 · registry result, not featured evidence — NCT02791490 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 12.2%10 mgk NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results14.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 17%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.8%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.8% NCT02024477 · Phase 4 · registry result, not featured evidence 12.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 7.1%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02243176 · Phase 4 · registry result, not featured evidence 1.8% NCT01608724 · Phase 4 · registry result, not featured evidence 25.5% NCT01107886 · Phase 4 · registry result, not featured evidence 11.4%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 4.1% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 3.8%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.3%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 1.6%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 4.9%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 12.8%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 6.2% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 3.9% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 0% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence 5.1%5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination —Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination 4.4%DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination —Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 4.6%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT01606007 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01128153 · Phase 3 · registry result, not featured evidence 0% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 2.2%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 8.2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 27.1% NCT00614939 · Phase 3 · registry result, not featured evidence 1.4%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 5%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 7.7%100 mgl NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results10.1%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 80% NCT02556918 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence 0%Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence 0%Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination 0% NCT02256189 · Phase 4 · registry result, not featured evidence 0% NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 7.2%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 3.4% NCT01907854 · Phase 4 · registry result, not featured evidence 2% NCT01686932 · Phase 4 · registry result, not featured evidence 3.6%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.6%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.1%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 3.7%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0% NCT01131182 · Phase 4 · registry result, not featured evidence 3.1%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 4.7%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 0% NCT00686634 · Phase 4 · registry result, not featured evidence 2.7% NCT00729326 · Phase 4 · registry result, not featured evidence 4.2%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 10.5% NCT01485614 · Phase 3 · registry result, not featured evidence 6.5%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 6.7%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.1% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mgk influenza 15.5% (placebo 15.1%) nasopharyngitis 15.5% (placebo 14%) headache 13.3% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results5 mg influenza 16.2% (placebo 15.1%) nasopharyngitis 14.7% (placebo 14%) arthralgia 10.5% (placebo 6.7%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 15.1% (placebo 12.8%) nasopharyngitis 14.6% (placebo 14%) headache 14.1% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg arthralgia 16.3% (placebo 7.4%) headache 16.3% (placebo 16.8%) influenza 15.3% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg upper respiratory tract infection 15.1% (placebo 15.8%) urinary tract infection 13.2% (placebo 8.4%) headache 12.3% (placebo 16.8%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 13.7% (placebo 8.4%) upper respiratory tract infection 11.8% (placebo 15.8%) influenza 10.8% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5mg and 10mg nasopharyngitis 9.9% NCT02471404 · Phase 4 · registry result, not featured evidence · combination hyperlipidaemia 6.2% hyperlipidaemia 3.7% abdominal distension 1.2% NCT02243176 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 2.7% dizziness 2.6% NCT01608724 · Phase 4 · registry result, not featured evidence diabetes mellitus 6.5% (placebo 8.1%) dizziness 4.5% (placebo 4.2%) hypertension 4.2% (placebo 3.9%) NCT01107886 · Phase 4 · registry result, not featured evidence 5 mg nasopharyngitis 6.4% arthralgia 4.7% diarrhoea 4.2% NCT01006603 · Phase 4 · registry result, not featured evidence hypoglycaemia 6.8% diarrhoea 6.1% nasopharyngitis 5.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 5 mg toothache 7.7% (placebo 0%) acne 3.8% (placebo 0%) animal bite 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg aphthous ulcer 3.8% (placebo 0%) back pain 3.8% (placebo 2.6%) colitis 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 15.4% (placebo 2.6%) asthma 7.7% (placebo 0%) covid-19 7.7% (placebo 2.6%) NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.5 mg vitamin d deficiency 4.5% (placebo 6.6%) nausea 3.4% (placebo 0%) urinary tract infection 3.4% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg influenza 4.9% (placebo 2.6%) bronchitis 1.6% (placebo 0%) chronic sinusitis 1.6% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg covid-19 6.6% (placebo 2.6%) upper respiratory tract infection 6.6% (placebo 2.6%) urinary tract infection 4.9% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence dapagliflozin 10 mg, saxagliptin 5 mg urinary tract infection 13.7% upper respiratory tract infection 10.1% headache 7.9% NCT02419612 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.7% upper respiratory tract infection 5.2% headache 3.7% NCT02551874 · Phase 3 · registry result, not featured evidence · combination glomerular filtration rate decreased 4.1% pollakiuria 2.4% urinary tract infection 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on nasopharyngitis 7.8% headache 5.6% urinary tract infection 4.3% NCT02284893 · Phase 3 · registry result, not featured evidence · combination oropharyngeal pain 50% (placebo 25%) acne 25% (placebo 0%) cough 25% (placebo 25%) NCT01204775 · Phase 3 · registry result, not featured evidence headache 50% (placebo 0%) abdominal pain upper 25% (placebo 0%) back pain 25% (placebo 0%) NCT01434186 · Phase 3 · registry result, not featured evidence 5 mg QD hypoglycaemia 21.8% (placebo 23.8%) upper respiratory tract infection 2.6% (placebo 4.3%) urinary tract infection 2.6% (placebo 0.9%) NCT02104804 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 9.4% (placebo 10%) influenza 7.5% (placebo 7.5%) headache 6.9% (placebo 8.1%) NCT01646320 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.2% (placebo 6.8%) headache 5.9% (placebo 7.4%) nasopharyngitis 5.9% (placebo 4.9%) NCT01619059 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.2% (placebo 9.4%) diarrhoea 5.4% (placebo 3.9%) hypertension 5.4% (placebo 1.6%) NCT01128153 · Phase 3 · registry result, not featured evidence diarrhoea 5.8% urinary tract infection 5.1% nasopharyngitis 4.3% NCT00960076 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% diarrhoea 5.8% upper respiratory tract infection 5.8% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 8.4% (placebo 9.4%) NCT00918879 · Phase 3 · registry result, not featured evidence 5 mg + Metformin XR 1500 mg cough 6.5% NCT00918138 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.6% (placebo 7.9%) nasopharyngitis 6.3% (placebo 6.6%) upper respiratory tract infection 6.3% (placebo 7.3%) NCT00757588 · Phase 3 · registry result, not featured evidence · combination hypoglycaemia 28.2% (placebo 29.4%) anaemia 5.9% (placebo 8.2%) hypertension 5.9% (placebo 5.9%) NCT00614939 · Phase 3 · registry result, not featured evidence 5 mg headache 25% (placebo 18.8%) muscle spasms 25% (placebo 0%) infusion site pain 20% (placebo 12.5%) NCT00374907 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.3% (placebo 7.7%) NCT00698932 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.7% (placebo 4.5%) NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 100 mgl upper respiratory tract infection 13.1% dizziness 11.5% nasopharyngitis 9.2% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 30 more results100 mg/100 mg upper respiratory tract infection 15.1% dizziness 10.5% nasopharyngitis 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg upper respiratory tract infection 11.4% arthralgia 9.8% blood glucose increased 8.9% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg/200 mg upper respiratory tract infection 16.4% dizziness 12.4% influenza 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg any infections and infestations 6.3% (placebo 3.4%) upper respiratory tract infection 6.3% (placebo 3.4%) any nervous system disorders 5.1% (placebo 3.9%) NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 infection 2% (placebo 2%) headache 1% (placebo 1%) loss of appetite 1% (placebo 0%) NCT02556918 · Phase 4 · registry result, not featured evidence 100 mg headache 1.6% hypertension 1.6% diarrhoea 0% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 15.8% arrhythmic events 5.3% genital infection 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence light-headedness 7.7% (placebo 7.7%) paresthesias 7.7% (placebo 0%) nausea 0% (placebo 7.7%) NCT02639637 · Phase 4 · registry result, not featured evidence light-headedness 0% (placebo 7.7%) nausea 0% (placebo 7.7%) paresthesias 0% (placebo 0%) NCT02639637 · Phase 4 · registry result, not featured evidence · combination rash 0% (placebo 2.8%) NCT01859793 · Phase 4 · registry result, not featured evidence hypoglycemia 0% NCT02312063 · Phase 4 · registry result, not featured evidence urinary tract infection 1.4% wound infection 0% NCT01845831 · Phase 4 · registry result, not featured evidence · combination 50 mg erythema 38.5% hypoglycaemia 7.7% periodontitis 7.7% NCT02318693 · Phase 4 · registry result, not featured evidence diarrhoea 9.3% nausea 7.8% upper respiratory tract infection 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence hypoglycaemia 14% blood glucose decreased 6% NCT01686932 · Phase 4 · registry result, not featured evidence influenza 5.7% nasopharyngitis 4.7% diarrhoea 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination headache 5.7% nasopharyngitis 5.7% influenza 2.6% NCT01519674 · Phase 4 · registry result, not featured evidence · combination diarrhoea 5.3% influenza 5.3% headache 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination hyperglycemia 11.1% pressure ulcer/skin ulcer 11.1% hypoglycemia 3.7% NCT01378117 · Phase 4 · registry result, not featured evidence · combination hypoglycemia 6.9% pneumonia 6.9% urinary tract infection 6.9% NCT01378117 · Phase 4 · registry result, not featured evidence · combination headache 4.9% dizziness 3.9% hyperhidrosis 3.7% NCT01131182 · Phase 4 · registry result, not featured evidence nausea 15.7% vomiting 10.2% nasopharyngitis 8.7% NCT00870194 · Phase 4 · registry result, not featured evidence nausea 10.2% nasopharyngitis 7.8% headache 7% NCT00870194 · Phase 4 · registry result, not featured evidence · combination nausea 37% vomiting 20.5% headache 12.3% NCT00729326 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 7.8% diarrhoea 4.5% nausea 3.9% NCT04017832 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.8% nasopharyngitis 15.8% upper respiratory tract infection 12.6% NCT01485614 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.1% upper respiratory tract infection 14.5% diarrhoea 11.3% NCT01760447 · Phase 3 · registry result, not featured evidence hypoglycaemia 20% upper respiratory tract infection 11.1% abdominal pain 8.9% NCT01760447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13% hypoglycemia 5.2% influenza 5.2% NCT03115112 · Phase 3 · registry result, not featured evidence diarrhoea 7.9% (placebo 4.8%) NCT02791490 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dAssessment timepoints differ: 54 weeks versus 156 weeks.
- eTrial phases differ: Phase 4 versus Phase 3.
- fThe reported result categories differ.
- gAssessment timepoints differ: 26 weeks versus 52 weeks.
- hAssessment timepoints differ: 26 weeks versus 24 weeks.
- iAssessment timepoints differ: 20 weeks versus 26 weeks.
- jAssessment timepoints differ: 8 weeks versus 24 weeks.
- kPopulation comparability has not been reviewed for 38 of these studies.
- lPopulation comparability has not been reviewed for 33 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Saxagliptin
show 8 more results
show 6 more results
show 3 more results
show 4 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
+ 38 further endpoints in the CSV export.
Sitagliptin
show 3 more results
show 3 more results
show 1 more result
show 2 more results
show 1 more result
show 2 more results
+ 63 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Saxagliptin's landscape · Sitagliptin's landscape